How MBA was paid
$7.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Marianne De Backer, M.Sc., Ph.D., MBAPresident, Chief Executive Officer and Director | $950,000 | — | $2,296,800 | $3,507,360 | $1,002,750 | $77,135 | $7,834,045 |
| Vanina de Verneuil, J.D.Executive Vice President, General Counsel and Corporate Secretary | $506,333 | — | $334,950 | $511,490 | $329,648 | $8,363 | $1,690,784 |
| Mark Eisner, M.D., M.P.H.Executive Vice President and Chief Medical Officer | $660,833 | $375,000 | $382,800 | $584,560 | $354,291 | $14,000 | $2,371,484 |
| Jason O’Byrne, MBAExecutive Vice President and Chief Financial Officer | $534,417 | $150,000 | $382,800 | $584,560 | $286,051 | $14,000 | $1,951,828 |
What changed and why
- $7.8MMarianne De Backer received total compensation of $7,834,045 in 2025, down from $9,255,903 in 2024.
- 96%The advisory vote on executive compensation received approximately 96% support at the 2025 annual meeting.
- The majority of each named executive officer's compensation is at-risk and tied directly to performance.
- No special equity awards or off-cycle compensation adjustments were granted in 2025.
- Annual incentive plan payouts reflected above-target corporate attainment based on key clinical and strategic achievements.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.